Skip to main content
Fig. 6 | Parasites & Vectors

Fig. 6

From: Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice

Fig. 6

Evaluation of intranasal LaAg vaccine associated with ADDAVAX®. C57Bl/6-UFF mice received 10 μg of LaAg (10 μl) associated or not with ADDAVAX (10 μl) by the intranasal route on days -14 and -7 of infection. Non-vaccinated controls received PBS alone. On day 0, animals were infected with 5 × 105 promastigotes of L. amazonensis (Josefa strain). a Lesion sizes were measured at the indicated days and expressed as the difference of thickness between non-infected and infected footpads. b Parasite load was measured on day 70 of infection and expressed as the mean number of parasites in each footpad. The data (means ± standard deviations; n = 5–6) are representative of three independent experiments producing the same result profile. *P ≤ 0.05: LaAg in comparison to PBS controls; # P ≤ 0.05: b LaAg in comparison to LaAg + ADDAVAX; +P ≤ 0.05; LaAg + ADDVACS in comparison to PBS controls Test statistics for a are provided in Table 3. b LaAg in comparison to PBS: t (8) = 5.788, P = 0.0022; LaAg in comparison to LaAg + Addavacs: (t (8) = 6.501, P = 0.0013)

Back to article page